SCOPUS 정보 검색 플랫폼

Volumn 46, Issue 4, 2009, Pages 338-340

Determination of fibroblast growth factor 23

(7) Heijboer, Annemieke C a Levitus, Marieke a Vervloet, Marc G a Lips, Paul a Ter Wee, Piet M a Dijstelbloem, Hilde M a Blankenstein, Marinus A a

a VU UNIVERSITY MEDICAL CENTER (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID; FIBROBLAST GROWTH FACTOR 23;

ARTICLE; BLOOD LEVEL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HORMONE DETERMINATION; HUMAN; HYPOPHOSPHATEMIC RICKETS; IMMUTOPICS ASSAY; KAINOS ASSAY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; PERFORMANCE; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY;

BIOLOGICAL ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBROBLAST GROWTH FACTORS; HUMANS; REPRODUCIBILITY OF RESULTS;

EID: 67650803410 PISSN: 00045632 EISSN: 00045632 Source Type: Journal
DOI: 10.1258/acb.2009.009066 Document Type: Article

Times cited : (69)

References (8)

1
- 57449105957
- Endocrine functions of bone in mineral metabolism regulation
- Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-3828
- (2008) J Clin Invest , vol.118 , pp. 3820-3828
- Quarles, L.D.¹

2
- 20244368616
- Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia
- DOI 10.1056/NEJMoa020881
- Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-1663 (Pubitemid 36459471)
- (2003) New England Journal of Medicine , vol.348 , Issue.17 , pp. 1656-1663
- Jonsson, K.B.¹ Zahradnik, R.² Larsson, T.³ White, K.E.⁴ Sugimoto, T.⁵ Imanishi, Y.⁶ Yamamoto, T.⁷ Hampson, G.⁸ Koshiyama, H.⁹ Ljunggren, O.¹⁰ Oba, K.¹¹ Yang, I.M.¹² Miyauchi, A.¹³ Econs, M.J.¹⁴ Lavigne, J.¹⁵ Juppner, H.¹⁶

3
- 18744371012
- Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia
- DOI 10.1210/jc.2002-021105
- Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002;87:4957-4960 (Pubitemid 35316332)
- (2002) Journal of Clinical Endocrinology and Metabolism , vol.87 , Issue.11 , pp. 4957-4960
- Yamazaki, Y.¹ Okazaki, R.² Shibata, M.³ Hasegawa, Y.⁴ Satoh, K.⁵ Tajima, T.⁶ Takeuchi, Y.⁷ Fujita, T.⁸ Nakahara, K.⁹ Yamashita, T.¹⁰ Fukumoto, S.¹¹

4
- 33744956771
- Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia
- DOI 10.1210/jc.2005-2105
- Imel EA, Peacock M, Pitukcheewanont P, et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 2006;91:2055-2061 (Pubitemid 43854981)
- (2006) Journal of Clinical Endocrinology and Metabolism , vol.91 , Issue.6 , pp. 2055-2061
- Imel, E.A.¹ Peacock, M.² Pitukcheewanont, P.³ Heller, H.J.⁴ Ward, L.M.⁵ Shulman, D.⁶ Kassem, M.⁷ Rackoff, P.⁸ Zimering, M.⁹ Dalkin, A.¹⁰ Drobny, E.¹¹ Colussi, G.¹² Shaker, J.L.¹³ Hoogendoorn, E.H.¹⁴ Hui, S.L.¹⁵ Econs, M.J.¹⁶

5
- 49249104701
- Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis
- Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592
- (2008) N Engl J Med , vol.359 , pp. 584-592
- Gutierrez, O.M.¹ Mannstadt, M.² Isakova, T.³

6
- 27644534466
- Comparison of two assays for fibroblast growth factor (FGF)-23
- DOI 10.1007/s00774-005-0625-4
- Ito N, Fukumoto S, Takeuchi Y, et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005;23:435-440 (Pubitemid 41571109)
- (2005) Journal of Bone and Mineral Metabolism , vol.23 , Issue.6 , pp. 435-440
- Ito, N.¹ Fukumoto, S.² Takeuchi, Y.³ Yasuda, T.⁴ Hasegawa, Y.⁵ Takemoto, F.⁶ Tajima, T.⁷ Dobashi, K.⁸ Yamazaki, Y.⁹ Yamashita, T.¹⁰ Fujita, T.¹¹

7
- 33748324520
- Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: Implication for treatment decisions
- DOI 10.1373/clinchem.2006.071589
- Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006;52:1771-1776 (Pubitemid 44330713)
- (2006) Clinical Chemistry , vol.52 , Issue.9 , pp. 1771-1776
- Cantor, T.¹ Yang, Z.² Caraiani, N.³ Ilamathi, E.⁴

8
- 37249060846
- What does serum fibroblast growth factor 23 do in hemodialysis patients?
- Emmett M. What does serum fibroblast growth factor 23 do in hemodialysis patients? Kidney Int 2008;73:3-5
- (2008) Kidney Int , vol.73 , pp. 3-5
- Emmett, M.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.